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ABSTRACT Schizophrenia is an idiopathic disorder that affects approximately 1% of the human population,
and presents with persistent delusions, hallucinations, and disorganized behaviors. Antipsychotics are the
standard pharmacological treatment for schizophrenia, but are frequently discontinued by patients due to
inefficacy and/or side effects. Chronic treatment with the typical antipsychotic haloperidol causes tardive
dyskinesia (TD), which manifests as involuntary and often irreversible orofacial movements in around 30% of
patients. Mice treated with haloperidol develop many of the features of TD, including jaw tremors, tongue
protrusions, and vacuous chewing movements (VCMs). In this study, we used genetically diverse Collab-
orative Cross (CC) recombinant inbred inter-cross (RIX) mice to elucidate the genetic basis of antipsychotic-
induced adverse drug reactions (ADRs). We performed a battery of behavioral tests in 840 mice from 73 RIX
lines (derived from 62 CC strains) treated with haloperidol or placebo in order to monitor the development of
ADRs. We used linear mixed models to test for strain and treatment effects. We observed highly significant
strain effects for almost all behavioral measurements investigated (P , 0.001). Further, we observed strong
strain-by-treatment interactions for most phenotypes, particularly for changes in distance traveled, vertical
activity, and extrapyramidal symptoms (EPS). Estimates of overall heritability ranged from 0.21 (change in
body weight) to 0.4 (VCMs and change in distance traveled) while the portion attributable to the interactions
of treatment and strain ranged from 0.01 (for change in body weight) to 0.15 (for change in EPS). Interestingly,
close to 30% of RIX mice exhibited VCMs, a sensitivity to haloperidol exposure, approximately similar to the
rate of TD in humans chronically exposed to haloperidol. Understanding the genetic basis for the suscep-
tibility to antipsychotic ADRs may be possible in mouse, and extrapolation to humans could lead to safer











Schizophrenia is a chronic, severe, and disabling brain disorder that
affects about 1% of the population worldwide and is associated with
substantial morbidity, mortality, and personal and societal costs
(Saha et al. 2007; World Health Organization 2008; Laursen et al.
2012; Cloutier et al. 2016). Onset typically occurs in adolescence
or early adulthood with the emergence of a number of symp-
toms, including hallucinations, delusions, and disorganized behavior
(American Psychiatric Association. 2013). Antipsychotic medications
are the mainstay of treatment for schizophrenia, but as much as 75%
of patients discontinue assigned treatments due to side effects and/or
inefficacy over relatively short periods of time (Lieberman et al. 2005).
Deciphering the pharmacogenetics of antipsychotics could eventually
allow the development of predictive algorithms, such that physicians
could predict which patients are prone to develop side effects or less
likely to achieve a therapeutic response. Advances in this arena could
lead to safer and more efficacious therapeutic interventions for the
treatment of schizophrenia.
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Haloperidol is a high-potency, typical, first-generation antipsychotic
whose use is associated with motoric adverse drug reactions (ADRs),
including tardive dyskinesia (Soares-Weiser and Fernandez 2007),
involuntary orofacial movements, and extrapyramidal symptoms
(i.e., dystonia and Parkinsonism) (Miller et al. 2008). There is sub-
stantial inter-individual variation in liability to these ADRs and direct
and indirect evidence suggest a role for genetic variation (Lerer et al.
2005; Patsopoulos et al. 2005; Bakker et al. 2006). There is significant
heterogeneity in therapeutic response to antipsychotics (Lieberman
et al. 2005), with roughly equal proportions of patients experiencing
remission, partial response, and no benefit. Vacuous chewing move-
ments (VCMs), which present in rodents as purposeless mouth
openings in the vertical plane, are a valid rodent model for the
human pharmacogenetic phenotype of tardive dyskinesia (Tomiyama
et al. 2001; Turrone et al. 2002; Crowley et al. 2012b; Crowley et al.
2014). Indeed, using 27 genetically diverse inbred mouse strains, we
previously showed that chronic haloperidol treatment (60 days)
can bring on VCMs that persist for 1.5 years, that VCMs and
extrapyramidal side effects are highly heritable (0.9), and that
there are strong strain effects (Crowley et al. 2012a). Genome-wide
association mapping of these same 27 inbred strains nomi-
nated 50 genes for association with haloperidol-induced ADRs
(Crowley et al. 2012b). Furthermore, using RNA sequencing of
striatal tissue from mice chronically treated with haloperidol, we
previously observed an overlap between the genetic variation
underlying the pathophysiology of schizophrenia and the molec-
ular effects of haloperidol (Kim et al. 2018).
Traditional recombinant inbred strains that are generated by
crossing two parental inbred strains followed by 20 generations of
inbreeding by brother-sister mating, lack genetic diversity, and are
limited by the number of available strains (e.g., C57BL6/J, 129S1,
BALB/c, etc.). In contrast, the Collaborative Cross (CC) (Threadgill
et al. 2002; Churchill et al. 2004; Collaborative Cross Consortium
2012) is a panel of recombinant inbred (RI) mouse strains, derived
from eight founder laboratory strains, that was designed as an
optimized murine model of heterogeneous human populations
(Churchill et al. 2004; Aylor et al. 2011; Threadgill et al. 2011;
Collaborative Cross Consortium 2012). The CC captures the com-
plexity of the mammalian genome, and is an important resource for
mapping complex traits and system genetics efforts (Aylor et al. 2011;
Kelada et al. 2012; Ferris et al. 2013; Gralinski et al. 2015; Gralinski
et al. 2017; Shorter et al. 2017; Srivastava et al. 2017). The CC has also
been a source of new models of human diseases (Rogala et al. 2014;
Graham et al. 2016; Mcmullan et al. 2018; Orgel et al. 2019). By
mating different CC strains, we can generate recombinant inbred
inter-crosses (CC-RIX) (Zou et al. 2005; Schoenrock et al. 2018).
CC-RIX are outbred but their genomes are completely reproducible
(by mating their parental CC strains) and thus are an intriguing
model of the genetic diversity akin to that in human populations (Zou
et al. 2005; Liu et al. 2018). The genetic diversity of CC-RIX enables
the study of parent-of-origin effects and their phenotypic character-
ization has demonstrated that there are strong strain effects in some
measures (Crowley et al. 2015; Schoenrock et al. 2018). Using
standard inbred lines, we previously demonstrated that we could
effectively deliver haloperidol at human-like steady-state concentra-
tions, that steady-state plasma haloperidol concentration is a trait
with relatively high heritability, and that there were substantial RI
strain differences in the vulnerability to VCMs (Crowley et al. 2012a;
Crowley et al. 2012b; Crowley et al. 2014).
In this study, we generated 840 mice and performed extensive
phenotypic characterization of 777 mice representing 73 RIX lines
chronically treated with haloperidol or placebo in order to gain
insight into the genetic basis of ADRs. We performed a battery of
behavioral tests, including open field activity, the inclined screen test,
and video recordings of VCMs, in order to examine the strain and
treatment effects of chronic haloperidol exposure. Using linear mixed
models we showed that RIX lines exhibited strong strain effects and
strain-by-treatment interactions, supporting the hypothesis of a
significant differential contribution of their genetic background to
haloperidol-induced ADRs. The fact that RIX lines displayed a range
of responses to haloperidol-induced ADRs, with a distribution that is
comparable to the susceptibility of haloperidol-ADRs in the human
population, supports their use as a model for the study of pharma-
cogenomics and additional phenotypes.
MATERIALS AND METHODS
Mice
A total of 840 mice were tested, including 423 females (210 haloper-
idol, 213 placebo) and 417 males (210 haloperidol, 207 placebo).
These mice represented a total of 73 RIX lines which were derived
from 62 CC strains and tested across 51 batches. See Table 1 for
summary information on mice with complete data for each pheno-
type. RIX mice used in this study were born between 5/7/2012 and 6/
16/2014. All mice were bred from CC strains from the Systems
Genetics Core Facility at the University of North Carolina (http://
csbio.unc.edu/CCstatus/index.py?run=availableLines). CC mice were
crossed to generate RIX mice as shown in Figure 1 and Figure S1. Pups
were weaned at 3 weeks of age and housed two animals per cage, with
one randomly assigned to receive haloperidol and the other placebo.
Animals were maintained on a 14 hr light/10 hr dark schedule with
water and food available ad libitum. All testing procedures were
conducted in strict compliance with the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal Resources,
National Research Council 1996) and approved by the Institutional
Animal Care and Use Committee of the University of North Carolina.
The study design of our 6-week haloperidol phenotyping protocol
is summarized in Figure 1. Most RIX lines (63 of 73) included
12 animals, although some lines had fewer (two were composed of
only two animals each) and others more (one line included 18 mice).
Given the number of mice assayed in this study and the battery of
tests we employed, it was unfeasible to generate and test all mice in a
single batch. Our mixed models include batch as a random effect to
account for this possible confounder.
Haloperidol exposure
Eight-week old mice (67 days) were implanted with slow-release
haloperidol pellets (3.0 mg/kg/day; Innovative Research of America;
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Sarasota, FL, USA) (Fleischmann et al. 2002) or placebo and treated
for 30 days for a chronic haloperidol administration paradigm. All
experimental procedures were randomized to minimize batch arti-
facts (Leek et al. 2010) (e.g., assignment to haloperidol or placebo;
cage; order of dissection; and assay batch). Experimenters were blind
to treatment status.
We have previously demonstrated that this procedure reliably
yields human-like steady-state concentrations of haloperidol (typ-
ically 3.75–19 ng/ml) (Hsin-Tung and Simpson 2000) in blood
plasma and brain tissue. This chronic dosing paradigm reliably
results in VCMs (an established model of extrapyramidal symp-
toms) (Turrone et al. 2002) in multiple mouse strains (Crowley
et al. 2012b; Crowley et al. 2012a; Crowley et al. 2014). Haloper-
idol pellets were implanted subcutaneously with a trocar under
2 min of isoflurane anesthesia to minimize handling stress and
pain. Two pellets of incremental dosages were implanted 2 days
apart to compensate for varying body weights and to minimize
acute sedation (Crowley et al. 2012a). Placebo-treated animals
were implanted with pellets containing the same matrix material
but no drug. Following pellet implantation, we positioned food
and water near the surface of the bedding, since movement can be
compromised in a strain-specific manner due to variable degrees
of haloperidol-induced extrapyramidal side effects.
Open field activity (OFA)
Extrapyramidal side effects may appear as general motor deficits in
mice. Open field activity is a behavioral assay that measures general
locomotor activity, anxiety, and exploratory drive (Crusio 2013).
OFA was measured on days -7 and +28 relative to the start of drug
treatment (day 0). Spontaneous locomotor activity in the open field
(Crawley 1985) was measured for 30 min using a photocell-equipped
automated open field apparatus with a white Plexiglas floor and clear
Plexiglas walls (Superflex system, Accuscan Instruments, Columbus,
OH; arena measures 40 cm wide · 40 cm long · 30 cm high)
surrounded by infrared detection beams on the X, Y and Z-axes that
track the animals’ position and activity over the course of the
experiment. The apparatus is isolated within a 73.5 · 59 · 59 cm
testing chamber fitted with overhead fluorescent lighting (lux level
14). One to two hours before testing, cages were moved from the
housing room to the testing room. Following acclimation, animals
were removed from their home cage, immediately placed in the
corner of the open field arena, and allowed to freely explore the













BatchesMale Female Male Female
Distance 828 785 777 199 204 188 186 62 73 51
Vertical 828 785 777 199 204 188 186 62 73 51
Stereotypy 828 785 777 199 204 188 186 62 73 51
Centroid 828 785 777 199 204 188 186 62 73 51
VCM n/a 731 731 183 192 177 179 62 73 51
Weight 823 716 715 179 191 171 174 58 68 46
EPS 783 639 604 152 155 150 147 60 68 39
Plasmaa n/a 254 254 — — 125 129 48 53 37
a
applies only to haloperidol arm.
Figure 1 RIX breeding scheme, experimental design
and phenotyping pipeline. (a) CCmicewere crossed in a
quasi-loop design (See Figure S1) in order to generate
RIX lines with maximum genetic diversity. We tested up
to 12 animals per RIX line: 6 males (3 haloperidol,
3 placebo) and 6 females (3 haloperidol, 3 placebo).
(b) Mice were housed two per cage from weaning with
one designated for drug treatment and the other for
placebo treatment. To avoid batch effects, each RIX line
was tested across up to three batches. (c) RIX mice were
aged for 8 weeks before being added to the pheno-
typing pipeline. Phenotyping occurred “pre-drug”
(7 days before pellet implantation), after “acute drug”
treatment (on day 4; one day after split pellet implanta-
tion), and chronic treatment with haloperidol or placebo
(“chronic drug”: 28-35 days after pellet implantation).
Open field activity (OFA) was done both pre-drug and
after chronic drug treatment. The inclined screen test,
which measures extrapyramidal side effects (EPS) was
done both pre-drug and after acute drug treatment.
Vacuous chewing movements (VCMs) were measured
after chronic drug treatment.
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apparatus for a 30-minute test interval. Four phenotypes were
extracted from these activity data: total distance traveled (cm),
vertical activity (number of beam breaks on the Y-axis), stereotypy
(a measure of repetitive movements based on repeated breaking of the
same beam), and time spent in the central region of the chamber (a
measure of anxiety). Activity chambers were located inside of sound-
attenuating boxes equipped with houselights and fans.
Extrapyramidal side effects (EPS)
The inclined screen test (Barnes et al. 1990) was used as an index of
Parkinsonian rigidity and sedation. Mice were placed on a wire mesh
screen inclined at 45 and the latency to move all four paws was
recorded (to a maximum of 60 sec). EPS was measured at baseline
(day -5) and 24 hr after implantation of the second drug pellet (day 4),
since pilot work indicated that haloperidol-induced EPS was most
pronounced after acute, rather than chronic, drug treatment.
Orofacial movement scoring
Video recording of vacuous chewing movements (VCMs) was carried
out after 28 days post-treatment. To this end, mice were briefly
anesthetized with isoflurane and restrained for 25 min using a plastic
collar. Collars were made from two plastic semicircular pieces that were
adjusted based on neck size and to achieve the most comfortable
position for the mouse. The collar partially immobilized the mice at the
neck but still permitted head movement to allow for video recording of
jaw movements by JVC Everio digital camcorders. Digital video-
tapes were made using the protocol developed by Tomiyama et al.
(Tomiyama et al. 2001). The first 10 min of video were not analyzed in
order to allow the mice to adjust to the collar and to relax. The last
15 min of the video were scored for orofacial movement. Videos were
randomized and scored by a single-blinded rater to increase consis-
tency and to reduce any deviation or bias between raters. The rater was
trained by an expert and a set of standard training videos used in the
studies by Crowley et al. (Crowley et al. 2012a; Crowley et al. 2012b) to
align the rater with the correct identification of VCMs according to the
scoring from those previous studies. Drift was monitored by re-scoring
random videos throughout the course of the study.
The movements that were specifically analyzed and counted were
tongue protrusions, jaw tremors, overt chewing movements, and subtle
chewingmovements. Individual events of eachmovement were counted.
Subtle chewing movements were defined as instances of vertical jaw
movement in which the inside cavity of the mouth could not be seen
and the jaw was not open for a long period of time. Overt chewing
movements occurred when a larger vertical movement was observed in
which the cavity could be seen and the jaw was open for an extended
length of time. The videos were scored using The Observer XT (Noldus
Inc., Wageningen, Netherlands) observational data analysis program.
Tissue collection
Mice were killed on day +32 relative to the start of drug treatment by
cervical dislocation. We collected blood plasma from haloperidol-treated
mice at this time using EDTA-treated tubes in order to measure
haloperidol drug concentration. Blood was centrifuged to isolate plasma.
Haloperidol assays were performed using mass spectrometry at the
Analytical Psychopharmacology Laboratory located at the Nathan Kline
Institute for Psychiatric Research (Orangeburg, NY, USA).
Statistical models
As shown in Table 1, the phenotypes studied can be grouped into
three classes depending on the nature of outcome ascertainment;
correspondingly, three separate statistical models were employed. For
the open field activity, EPS, and body mass phenotypes, outcomes
were ascertained on two occasions (pre- and post-treatment) in both
arms. VCMs were measured on a single occasion (post-treatment) in
both arms. Blood plasma phenotype was also only measured post-
treatment, but naturally only applies to the haloperidol arm.
For the open field, EPS, and body weight phenotypes, the differ-
ence between pre- and post-treatment measurements were taken and
log-transformed for body weight. The mixed model employed for
these phenotypes was:





where Y refers to the vector of transformed responses, xpre to the
vector of pre-treatment phenotype values, xtmt is a vector of treatment
indicators, xsex controls for sex, and xsextmt controls for the in-
teraction of sex and treatment. Each gj refers to a random effect
vector associated with the jth random effect. The gj’s correspond to
the batch, strain, strain-by-treatment, strain-by-sex, and strain-by-
sex-by-treatment effects (henceforth referred to as effects 1-5, re-
spectively). and have associated random design matrices Z1 2 Z5. We
assume that the gj’s are mutually independent and gj  Nð0;s2j Iqj·qjÞ.
Further, the error term e  Nð0;s2e  In·nÞ, independent of the random
effects. Details on the construction of the associated random design
matrices (Z1 2 Z5) are included in File S1.
A single VCM phenotype was derived by summing the number
subtle and overt VCM, tongue movements, and tremors, in order to
give each movement equal weight. In previous work by Crowley et al.
(Crowley et al. 2012a), when 27 inbred strains were treated with
chronic haloperidol, the behavioral domains that were measured
loaded onto two factors, one of which was primarily haloperidol-
induced orofacial movements. While we did not observe the same
separation in our data, we did perform a factor analysis and a
principal component analysis on the four VCM variables to explore
alternative data reduction approaches. When using the latent factor
or the first principal component as the dependent variable, the
inference was indistinguishable from that described below. For this
phenotype, the following model was employed, with the term to
control for the pre-treatment value excluded, as follows:




Haloperidol blood concentration was log-transformed, and the fol-
lowing model was employed. This model controls for three random
effects: batch, strain, and sex (1, 2, and 4):
Y ¼ b0 þ b3  xsex   þ   Z1g1 þ Z2g2 þ Z4g4 þ e:
All models were fit in SAS/STAT 14.1 software, Version 9.4 of the SAS
System for Linux (Sas Institute Inc. 2015), using PROCMIXED. This
procedure allows the user to specify flexible design matrices, but the
required syntax to achieve the desired correlation structure is non-
trivial, and sample code is included in File S1.
Data availability
All data from this study have been deposited in the Mouse Phenome
Database (https://phenome.jax.org/projects/Xenakis1). Available CC
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strains can be obtained from the Systems Genetics Core Facility
at the University of North Carolina (http://csbio.unc.edu/CCstatus/
index.py?run=availableLines). Table S1 describes the CC strains used
to generate the RIX lines that were part of the study. Figure S1 shows
the mating scheme used to cross CC strains and generate RIX with
maximum genetic diversity. Figure S2 shows haloperidol-induced
changes in behavioral measures. Figure S3 shows the raw data for RIX
mice treated with haloperidol or placebo, for the centroid time and
stereotypy measures of OFA. Figure S4 shows RI strain-by-treatment
and strain prediction intervals for stereotypy, centroid, and EPS.
Figure S5 presents raw data and strain-by-treatment predictions for
body weight of RIX mice treated with haloperidol or placebo. Figure
S6 shows CC strain-level predictions for plasma haloperidol levels.
Figure S7 presents the distributions of transformed phenotypes used
in our genetic mapping effort. Figure S8 presents the results of our
genetic mapping effort. Figure S9 presents the results of our small
simulation study to illustrate a lack of power to detect a significant
locus in the presence of a strong polygenic effect. Figure S10 compares
the pre-treatment distributions of various behavioral measures be-
tween the CC-RIX, the CC diallel study (Crowley et al. 2014), and a
survey of 27 mouse strains (Crowley et al. 2012a; Crowley et al.
2012b). File S1 includes sample code for linear mixed models. File S2
includes the power simulation of QTL mapping. Supplemental
material available at figshare: https://doi.org/10.25387/g3.9757208.
RESULTS
Generation of RIX lines from CC strains
In this study, we used RIX mice derived from the genetically diverse
CC in order to understand the effects of haloperidol-induced ADRs,
using a battery of behavioral tests as a means of doing a compre-
hensive phenotypical characterization. To maximize genetic diversity
and test outbred mice with reproducible genomes, we generated RIX
mice by crossing males and females from two different CC RI strains
(Figure 1a) in a quasi-loop design (Figure S1). This quasi-loop design
used all RI genomes available at the time, generating a mostly
uniformly structured population, potentially expanding the analytical
possibilities beyond simple additive models, and providing a system-
atic approach to detect regulatory variation including parent-of-
origin effects. We performed a battery of behavioral tests in 840 mice
from 73 RIX lines (derived from 62 CC strains) treated with halo-
peridol or placebo in order to monitor the development of ADRs.
Figure 1c details the phenotyping pipeline for this study. Mice were
entered into the phenotyping pipeline at 8 weeks of age and behav-
ioral assays were carried out as detailed in Materials and Methods.
Below, we provide both descriptive as well as model-based results for
the behavioral phenotypes examined using the CC-RIX.
Descriptive data
CC-RIX mice exhibit reduced open field activity after chronic
treatment with haloperidol: The raw data are visualized at the
marginal (that is, not strain-specific) level in a series of density plots
(Figures 2a-d) that illustrate the densities for each phenotype. Open
field activity decreased from pre- to post-treatment for mice treated
with placebo or haloperidol (Figure 2a-c). This is visualized as a left-
shift in the distribution curve, for all phenotypes except for stereotypy
(Figure 2d). This was expected for both cohorts, as mice are known to
spend less time exploring the open field chamber when re-exposed,
due to lack of novelty. For distance traveled (Figure 2a; Figure S2a)
and vertical activity (Figure 2b; Figure S2b), the left-shift is far more
pronounced for the haloperidol treated mice, suggesting a strong
average treatment effect. The left-shift is more modest for time in
centroid (Figure 2c; Figure S2c), and not observed at all for stereotypy
(Figure 2d; Figure S2d). Note that this implies only that there is a lack
of a marginal effect. For stereotypy, although the raw data do not
suggest a treatment effect at the mean, treatment still affects indi-
vidual RIX strains differently (see below).
Acute haloperidol exposure results in increased time on inclined
screen test: The raw data from the inclined screen test (Figure 2e),
suggest an extreme effect of haloperidol. For pre-treatment and
placebo-treated mice the series cluster around zero; these mice move
almost immediately after being placed on the inclined screen. Con-
versely, the distribution for the haloperidol treated mice is bimodal,
exhibiting an extremely fat right tail, enriched with a noticeable
proportion of animals who are unable to move their four paws at all
within the 60-second experiment.
Chronic haloperidol treatment increases incidence of VCMs: The
raw data for VCM are visualized in the distribution curves in Figure
2f. Haloperidol-treated RIX mice show increased susceptibility to the
emergence of VCMs, as evidenced by the fattening of the right tail in
the haloperidol series vis-à-vis the placebo series. Note a small but
noticeable proportion of animals from both treatment paradigms do
not experience any VCMs.
Strain-level descriptive figures: Figures 2a-f and Figures S2a-d pro-
vide an overview at the population-average level. Figure 3, Figure S3,
and Figure S5b show the raw data at the RIX line level. For each line
the distribution of the phenotype (or change in phenotype, where
appropriate), is visualized in boxplots where the first and third
quartiles are visualized at the bottom and top of the boxes, re-
spectively, and the median as a black hash mark. The pink boxes
correspond to the placebo data and the blue to haloperidol. The
strains are organized by increasing difference between these strain-
level medians. These differences in medians are visualized as the
monotonically increasing series of red dots. Chronic haloperidol
exposure had divergent effects across OFA measures. For distance
traveled and vertical activity, more than half of the RIX lines display a
reduction in these OFA measures after haloperidol exposure (Figure
3a-b), while less than a quarter of RIX lines displayed changes in
stereotypy (Figure S3a), and centroid duration (Figure S3b) seemed
unaffected in most lines. The raw data for EPS showed that the
majority of RIX lines showed a delayed response in the inclined
screen test after haloperidol treatment (Figure 3c). Lastly, the raw data
for the VCM measure showed that more than half of the RIX lines
displayed higher incidence of VCMs after haloperidol treatment
(Figure 3d).
Model-fitting results
Hypothesis Tests: The main model results are in Table 2, which
includes results for all eight phenotypes assayed in our experiment.
For ease of readability, some p-values were also not explicitly listed,
but rather the level at which they were significant is simply indicated
in footnotes. The first four rows of the table contain the fixed effect
estimates with p-values in parentheses. These p-values were com-
puted using the Kenward-Roger approximation to compute the
denominator degrees of freedom. The next four rows contain the
estimates for the variance components of interest (the batch effect has
been excluded), with the p-values computed from the likelihood ratio
tests (LRTs). The next four rows correspond to test statistics and
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p-values that involve multiple parameters; the numbers in the rows
corresponding to fixed effects are F-statistics, and those in the rows
corresponding to tests of random effects are likelihood ratio statistics.
One salient result is the strongmarginal (fixed) effect of treatment,
which is highly significant for most phenotypes. Confirming the
results from the exploratory analyses above, it is not significant in the
centroid and stereotypy models, however, and only weakly significant
in the model for body weight. Note, however, that the strain effect is
highly significant for all models, including centroid and stereotypy.
The random treatment effects are also significant for all phenotypes
except body weight (Figure S5).
Best linear unbiased predictions (BLUPS) to visualize CC strain
level predictions: The main model results included in Table 2 provide
evidence of the existence of strain and strain-by-treatment interac-
tions. However, determining which parental (RI) strains contribute
most is also of interest; i.e., we are interested in the levels of the
random effects not just the estimates of the variance components. An
explanation of the approach we employed to illustrate these parental
strain contributions benefits from some notational simplification. In
general, the models we fit can be written in the most concise matrix
form as follows:
Y ¼ Xbþ Zg þ e
where matrices are visualized in bold. Y corresponds to the phenotype
vector of interest, X is a matrix that accommodates all the fixed effect
covariates with associated parameter vector b. In this formulation, Z
and g are concatenations of the random design matrices and random
effects vectors. All distributional assumptions from above remain. The
variance of Y , denoted V , can therefore be written as follows:
V ¼ ZGZ9þ s2eI
where G  is the variance of g. When the estimate of G is full rank (i.e.,
when none of the model’s variance components are estimated at
zero), the predictions of the random effects vector are:
Figure 2 Overlaid series of density plots of individual behavioral measures for haloperidol- and placebo-treated mice, before (pre) and after (post)
chronic drug treatment. The gray series is comprised of the combined pre-treatment data for the placebo- and haloperidol-treated samples. Pre-
treated data were combined, as haloperidol- and placebo-treated animals were indistinct from each other prior to treatment. The pink and blue
series correspond to the post-treatment densities for placebo- and haloperidol-treated samples, respectively. (a) Distance traveled (cm) from OFA.
(b) Vertical activity (beam breaks) from OFA. (c) Centroid time (seconds) from OFA. (d) Stereotypy (beam breaks) from OFA. (e) EPS from inclined
screen test (seconds). (f) VCMs after chronic treatment with haloperidol or placebo.
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ĝ ¼ ĜZ9V̂21ðY2Xb̂Þ
These predictions are commonly referred to as the Best Linear
Unbiased Predictors (BLUPs) of g. We extracted the relevant portion
of this BLUP vector (recall g contains all the random effects in the
model) and plotted these strain level predictions in ascending order
for all phenotypes (Figure 4, Figure S4, Figure S5c-d, and Figure S6).
The absolute height of each bar corresponds to its 95% prediction
interval. Due to the small number of samples per RIX, there is little
power to differentiate between the RI effects: in comparing two strain
predictions, their intervals tend to overlap, except when comparing
strains at the extremes. Under the assumption of additive strain
effects, these strain-level predictions can be used to predict which RIX
lines will exhibit extreme phenotypes.
Strong correlations across phenotypes and behavioral measures:We
can leverage information across phenotypes to find strains that have
consistently extreme predictions, and use this information to actually
inform future experiments by selecting strains that have the most
extreme results. Here, we show that the strain predictions are
correlated across phenotypes, as are strain-by-treatment interactions.
To assess this correlation, we used the Pearson correlation coefficient
and present the results in the correlograms in Figure 5. The first panel
applies to the strain predictions and the second to the strain-by-
treatment interactions (note that the blood haloperidol concentration
appears only in this second panel; although the relevant random
effects were termed “strain” effects in the model for this phenotype,
they were only predicted in haloperidol-treated mice). For the
additive strain effects, there are two salient results. The distance,
vertical and body weight phenotypes are correlated, with changes in
horizontal distance correlating highly with changes in vertical beams
broken. Further, those strains with the largest decreases in the
phenotypes exhibited the smallest increases in weight, as expected.
The other two open field phenotypes exhibit some correlation with
VCM. Increased time spent in centroid is associated with fewer VCM,
while increased stereotypy is associated with increased VCM. The
correlation manifests in the strain-by-treatment effect as well, with
the effect of treatment on changes in distance, vertical, and centroid
Figure 3 RIX lines exhibited differential
sensitivity to haloperidol-induced changes
in OFA, EPS, and VCMs. (a) Box plots of
individual OFA measures across all pheno-
typed RIX lines, organized according to
their sensitivity to haloperidol-induced
changes in distance traveled. (b) Vertical
activity. (c) EPS. (d) VCMs
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effects all being correlated. Further, the effect of treatment on the
changes in distance and time spent in centroid are inversely pro-
portional to the effect of treatment on body weight.
QTL mapping of behavioral traits: We performed genetic mapping
for each of the eight phenotypes using R/qtl2 (Broman et al. 2019).
For the six phenotypes with pre- and post-treatment measurements
we computed the difference in pre- and post-treatment phenotypes as
above, and then took the difference between cagemate values (sub-
tracting the value for the haloperidol treated mouse from the value for
the placebo-treated mouse). We controlled for sex and the average
pre-treatment value (the average of the two cagemate values) as fixed
effects. For the VCM phenotype, we used the difference in total VCM
between cagemates as the phenotype and controlled for sex as a fixed
effect. For plasma concentration, no differencing was necessary since,
by definition, this phenotype only applies to mice treated with
haloperidol; we controlled for sex as a fixed effect. All models
included a random effect that accounted for the genetic similarity
between the RIX samples. The model was fit at every marker on the
MegaMUGA genotyping platform (Morgan et al. 2015) in an attempt
to map the genetic effect of the eight CC founder alleles. The
distributions of the (transformed) phenotypes are shown in Figure
S7 and the mapping results in Figure S8. The significance thresholds
visualized were derived based on 100 permutations; we identified no
compelling LOD peaks (Figure S9). The inability to find significant
associations is not unexpected, as these traits appear to be polygenic
and we would likely need amuch larger sample size to achieve enough
power to map these. A small simulation study is included in File S2 to
illustrate this point.
Consistent distribution with founder and CC strains:We also sought
to contextualize our findings to both the founder and CC strains. We
have previously explored the genetic architecture of ADR-associated
behavioral measures using a diallel cross of the eight genetically
diverse founder strains of the CC, and shown that 70% of the
variance in EPS is explained by parent-of-origin and additive effects
(Crowley et al. 2014). We compared the pre-treatment distributions
of the phenotypes for which comparable data were available in our
Figure 3 (Continued).
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data, the diallel cross, and the aforementioned survey of 27 mouse
strains (Crowley et al. 2012a; Crowley et al. 2012b; Crowley et al.
2014). As shown in Figure S10, the distributions largely accord
with our expectations; for the distance and vertical phenotypes,
the right tails of the RIX distributions are thicker than those for
the other samples, consistent with their expected hybrid vigor.
The same pattern is observed for VCM. Conversely, the mice in
the Strain Survey dataset are the heaviest, as they are enriched
with NZO samples, which were specifically bred to express this
phenotype.
DISCUSSION
Our study employed the genetically diverse CC-RIX mice to elucidate
the genetic basis of antipsychotic ADRs. We performed a battery of
behavioral tests in 840 mice from 73 RIX lines treated with haloper-
idol or placebo in order to monitor the development of ADRs.
CC-RIX lines displayed a wide-ranging response to haloperidol
treatment induced ADRs as captured in pre- and post-drug behav-
ioral measures. On average, treatment had a strong effect for every
phenotype, with the exceptions of centroid and stereotypy. However,
note that even for these phenotypes, there was significant between-
strain variability. The majority of the CC-RIX lines exhibited reduced
distance traveled and vertical activity upon haloperidol treatment,
with about a third of the RIX lines exhibiting little change in these
measures after exposure to haloperidol (Figure 3a-b). Centroid time
and stereotypy measures did not appear to be as sensitive to halo-
peridol induced response (Figure S3). The majority of RIX lines
showed a delayed response in the inclined screen test (EPS) after
haloperidol treatment (Figure 3c) and more than half of the RIX lines
displayed higher incidence of VCMs after haloperidol treatment
(Figure 3d). Interestingly, the prevalence of ADRs in the CC-RIX
population is analogous to what has been observed in humans, where
20–43% of patients treated with antipsychotics can develop tardive
dyskinesia (Halliday et al. 2002; Soares-Weiser and Fernandez 2007)
We used linear mixed models to test for the existence of strain and
treatment effects. Of note, all phenotype models that included a pre-
treatment fixed effect demonstrated significant regression to the
mean; subjects with higher pre-treatment scores experienced larger
reductions in the phenotype. We observed highly significant strain
effects for almost all behavioral measurements investigated (P ,
0.001). Further, we observed strong strain-by-treatment interactions
for most phenotypes, with particularly strong effects (P , 0.001) for
change in distance traveled and change in vertical activity, as well as
change in EPS. When viewing the BLUPs, it is important to keep
in mind that given the small sample sizes for each parental strain,
comparisons between the effects of individual pairs of parental
strains are not necessarily significant, even when the overall effects
are highly significant. To draw closer attention to the treatment
effect BLUPs, we indicate strains that are at the extreme for those
phenotypes with a substantial mean shift in Figure 3 and Figure S3
(in the direction consistent with this mean shift) in the rightmost
columns of Table S1. We flag strains that are in the most extreme
10%, finding that 27 strains had extreme responses for at least one of
these phenotypes, with eight of these being extreme for multiple
phenotypes.
Despite extensive efforts, we have a limited understanding of the
heritability of motoric ADRs in humans (Zhang and Malhotra 2011;
Drago et al. 2012; Crowley et al. 2014). As shown in Table 2, estimates
of heritability for the phenotypes measured using the CC-RIX ranged
from 0.21 (for change in body weight) to 0.4 (for both number of
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haloperidol treatment paradigm in 27 genetically diverse inbred
strains, we previously showed that haloperidol-induced ADRs (in-
cluding VCMs and EPS) are highly heritable (0.9), with strain being
a major predictor of phenotypic variation independently of haloper-
idol plasma levels (Crowley et al. 2012a). The discrepancy between
the heritability estimates found for VCMs between these studies is
likely due to the genetic diversity present in the CC-RIX, when
compared to the 27 inbred lines, and the lower heritability found
in the CC-RIX (h2 0.4), which is likely closer to the heritability of the
analogous trait (TD) in humans.
One major goal of our study was to identify specific genes driving
antipsychotic ADRs in the CC-RIX mice. Extensive work has been
done by us and others to map ADRs, including haloperidol-induced
catalepsy, using other mouse strains and crosses (Kanes et al. 1996;
Patel and Hitzemann 1999; Rasmussen et al. 1999; Hofstetter et al.
2008; Crowley et al. 2012b). For example, work by Kanes et al. who
Figure 4 RI strain-by-treatment (left) and strain (right) prediction intervals for: (a) Distance traveled, (b) vertical activity, and (c) VCMs.
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used the BXD recombinant inbred series (C57Bl/6J and DBA/2J)
identified a QTL on chromosome 9 near Drd2 (Kanes et al. 1996). In
our case, we performed genetic mapping for each of the eight
phenotypes using R/qtl2 (Figures S7-10) (Broman et al. 2019).
Because our goal was to map the underlying genetic effect of
treatment response, slightly different models than those described
above were employed. The inability to find significant associations is
not unexpected, as these traits appear to be polygenic and we would
likely need a much larger sample size to achieve enough power to map
these.
Our study supports the use of the CC-RIX mouse population for
pharmacogenomics studies. We observed that 30% of CC-RIX mice
exhibited a sensitivity to haloperidol exposure, evidenced by VCMs
and EPS, closely matching the proportion of humans that develop TD
after treatment with this antipsychotic. Given the significant impact
that antipsychotic ADRs and subsequent discontinuation of treat-
ment can have on patients, making headway in our understanding of
the genetic basis for the susceptibility to antipsychotic ADRs could
advance the development of safer and more effective therapeutic
approaches for the treatment of schizophrenia.
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